Zimmer Biomet Holdings, Inc. (ZBH) Earnings Call Transcripts

Zimmer Biomet Holdings, Inc.'s Latest Earnings Call - June 8, 2026

In the second quarter of 2026, Zimmer Biomet Holdings, Inc. reported revenues of $8.5 billion, which aligns with expectations but reflects a challenging transition year as the company restructures its sales force. The company guided for a modest revenue growth of 1% to 3% for the fiscal year, indicating a cautious outlook amidst ongoing changes. Management emphasized the importance of improving productivity in the U.S. market, where they noted a significant gap in performance compared to competitors, with average sales representatives handling only 7 cases per week versus 16.7 for leading rivals.

Reported metrics

Guidance from management

Management maintained its revenue growth guidance of 1% to 3% for 2026, indicating a cautious outlook as the company undergoes significant restructuring.

What management said

I guess the thing I'd add that the attention to change management has been critical on this, and that's ultimately the governor on how fast we go. So if we haven't checked all the boxes on how we had the conversations, do we know the potential repercussions we're not going to move forward until we're comfortable with that. I think that helps kind of make sure things stay on track.

So first of all, the reason why we guided EPS the way that we did in '26 is because we knew we're going to have some expenses associated with the transformation of the channel. When we move from a nondedicated and let me use 1 again to W2, is more expensive. -- right? To the you fully burden, you got benefits and whatnot. But then again, the assumption, and so far, the assumption has been validated is that as you inc...

What analysts pressed on

Analysts expressed concerns regarding the productivity challenges in the U.S. market and the potential impact of the sales force transition on revenue growth. There were also questions about the sustainability of gross margins moving forward, given the favorable tariff dynamics in Q1.

Main topics on the call

• Sales Force Transformation — Management is undergoing a significant restructuring of its sales force, moving from a non-dedicated to a fully dedicated model. CEO Ivan Tornos stated, "Everybody has to be fully dedicated to Zimmer Biomet," highlightin...
• Productivity Challenges — The company acknowledged a productivity gap, with U.S. sales reps averaging only 7 cases per week compared to competitors' 16.7. Tornos noted, "We have a productivity challenge in the U.S.," indicating a critical area fo...
• Guidance and Revenue Outlook — Zimmer Biomet maintained its revenue growth guidance of 1% to 3% for 2026, reflecting a cautious approach amid ongoing changes. Tornos expressed optimism for future growth, stating that the U.S. should grow at "mid-singl...
• Innovation and Product Launches — Management reported strong performance from new product launches, particularly in hips, with Tornos mentioning that products like Z1 and HAMR are "overperforming." However, he acknowledged challenges in the knee portfoli...

Read the full Zimmer Biomet Holdings, Inc. transcript (June 8, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 72 Zimmer Biomet Holdings, Inc. earnings call transcripts on record, spanning February 4, 2020 to June 8, 2026. Based on this history, Zimmer Biomet Holdings, Inc. reports quarterly. The most recent call on file is dated June 8, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

ZBH

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

72

First call

February 4, 2020

Most recent

June 8, 2026

Reporting cadence

quarterly